JNJ vs MRSN · P/E 17, rev $49.37B vs rev $40.5M
Johnson & Johnson (JNJ) versus Mersana Therapeutics Inc (MRSN) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. MRSN currently screens at market cap $145.4M.
Not investment advice. Open the JNJ and MRSN stock pages for the full models.
Not investment advice.